Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Shield CA Pegfilgrastim Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Shield of CaliforniaPolicy A56538MADD_0925

    Pegfilgrastim Coverage and Prior Authorization

    Customize your policy alerts

    Sign up for blue_shield_of_california Policy A56538MADD_0925 alerts

    Get alerted when Policy A56538MADD_0925 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This Medicare Part B drug policy governs medical-necessity and prior-authorization requirements for pegfilgrastim and its biosimilars, including use following hematopoietic cell transplantation, for Blue Shield of California Medicare Advantage members and participating providers.

    Policy Summary
    PayerBlue Shield of California
    PolicyPegfilgrastim Coverage and Prior Authorization
    Policy CodePolicy A56538MADD_0925
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit pegfilgrastim requests for the covered condition for prior authorization or preservice review.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1Covered condition specifically listed
    6 mgMaximum adult covered dose after transplant
    4 mg

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Maximum pediatric Neulasta dose under 45 kg
    One timeCoverage period for transplant indication
    8Pegfilgrastim HCPCS codes listed
    2Preferred step-therapy products

    Covered Indication

    Bone Marrow Transplantation

    Covered when all stated requirements are met.

    • Covered indication: The request is for use following bone marrow or hematopoietic cell transplantation.

      Bone Marrow Transplantation is the covered condition listed in the policy.

    • PPO product exception requirement: For a PPO request for Armlupeg, Fylnetra, Neulasta, Nyvepria, Stimufend, or Ziextenzo, the member has intolerance or a contraindication to the preferred pegfilgrastim products Fulphila and Udenyca that is not expected with the requested pegfilgrastim product.

      Applies to the specified PPO requests.

    Covered Codes and Dosing

    Covered HCPCS CodesHCPCSCovered
    J2506Injection, pegfilgrastim, excludes biosimilar, 0.5 mg
    Q5108Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
    Q5111Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
    Q5120Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg
    Q5122Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg
    Q5127Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg
    Q5130Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg
    Q5169Injection, pegfilgrastim-unne (armlupeg), biosimilar, 0.5 mg
    Adult Post-Transplant Dose
    Maximum doseUp to 6 mg
    RouteSubcutaneous administration
    TimingDay 1 following transplant
    Dose limitOne dose
    Pediatric Neulasta Post-Transplant Dose
    Patient populationPediatric patients weighing less than 45 kg
    Maximum doseUp to 4 mg
    RouteSubcutaneous administration
    TimingDay 1 following transplant
    Dose limitOne dose

    Authorization and Submission Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization/preservice review is required for requests under this policy before coverage can be determined.

    Note

    Route Oncology-Related Requests to Evolent

    Direct requests for oncology-related indications to Evolent. Providers may submit the prior authorization request through Evolent's CarePro Provider Portal.

    • Evolent medical-necessity policies are available under Blue Shield Oncology-Related Medication Policies.
    Step Therapy

    Preferred Pegfilgrastim Step Therapy

    Step therapy applies to members enrolled in Blue Shield Select (PPO) and Blue Shield Medicare (PPO) plans. Members newly initiating treatment with the listed products must first try both preferred pegfilgrastim products, Fulphila and Udenyca.

    Clinical Background

    Pegfilgrastim is a long-acting colony-stimulating factor used to support neutrophil recovery and reduce the duration of severe neutropenia in appropriate clinical settings. This policy specifically addresses its use following bone marrow or hematopoietic cell transplantation, including support for hematopoietic cell mobilization and post-transplant neutrophil recovery.

    Key Definitions

    Medically Accepted Indication
    DefinitionA use of a prescription drug or biological product approved under the Federal Food, Drug, and Cosmetic Act, or a use supported by one or more citations in CMS-approved compendia.
    Federal authoritySection 1861(t)(2)(B) of the Act
    Supporting authoritiesThe Federal Food, Drug, and Cosmetic Act and CMS-approved compendia
    Biosimilar
    DefinitionA biological product that is highly similar to an FDA-approved reference biologic.
    Clinical differencesThere are no clinically meaningful differences from the reference product.
    Relationship to reference biologic

    Initial Therapy for Bone Marrow Transplantation

    Initial Therapy for Bone Marrow Transplantation

    Initial therapy for the listed transplant indication is medically necessary when the following requirement is met.

    Initial transplant therapy

    • Transplant indication: The request is for pegfilgrastim following bone marrow or hematopoietic cell transplantation.
    • PPO product exception requirement: For a PPO request for Armlupeg, Fylnetra, Neulasta, Nyvepria, Stimufend, or Ziextenzo, document intolerance or a contraindication to the preferred pegfilgrastim products Fulphila and Udenyca that is not expected with the requested pegfilgrastim product.

      Applies to the specified PPO requests.

    Preferred Product Sequence

    Plan applicabilityRequired trial productsAffected products
    Blue Shield Select PPO and Blue Shield Medicare PPO membersTry both Fulphila and Udenyca firstArmlupeg, Fylnetra, Neulasta, Nyvepria, Stimufend, and Ziextenzo

    Transplant-Indication Quantity Limits

    Pegfilgrastim Quantity Limit
    Maximum doseUp to 6 mg
    RouteSubcutaneous administration
    TimingDay 1 following transplant
    Coverage frequencyOne dose
    Neulasta Quantity Limit
    Patient populationPediatric patients weighing less than 45 kg
    Maximum doseUp to 4 mg

    Preferred Biosimilar Products

    Billing Rule

    Fulphila must be tried with Udenyca

    For Blue Shield Select PPO and Blue Shield Medicare PPO members newly initiating Armlupeg, Fylnetra, Neulasta, Nyvepria, Stimufend, or Ziextenzo, Fulphila must be tried along with Udenyca before coverage of the requested product.

    • Preferred-product pairing: Fulphila and Udenyca.
    • Applies to newly initiated therapy with the specified products.
    Billing Rule

    Udenyca must be tried with Fulphila

    For Blue Shield Select PPO and Blue Shield Medicare PPO members newly initiating Armlupeg, Fylnetra, Neulasta, Nyvepria, Stimufend, or Ziextenzo, Udenyca must be tried along with Fulphila before coverage of the requested product.

    • Preferred-product pairing: Udenyca and Fulphila.
    Policy Summary
    PayerBlue Shield of California
    PolicyPegfilgrastim Coverage and Prior Authorization
    Policy CodePolicy A56538MADD_0925
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit pegfilgrastim requests for the covered condition for prior authorization or preservice review.
    SourceLink
    On This Page
    Covered IndicationCovered Codes and DosingAuthorization and Submission RequirementsClinical BackgroundKey DefinitionsInitial Therapy for Bone Marrow TransplantationPreferred Product SequenceTransplant-Indication Quantity LimitsPreferred Biosimilar Products
    • Affected products: Armlupeg, Fylnetra, Neulasta, Nyvepria, Stimufend, and Ziextenzo.
    • Preferred step-therapy products: Fulphila and Udenyca.
    Documentation Required

    Submit Medical-Necessity Documentation

    Submit clinical documentation supporting that the member meets all medical-necessity requirements.

    • Office chart notes
    • Laboratory results
    • Other relevant clinical information
    Documentation Required

    Document Preferred-Product Exceptions

    For PPO requests involving Armlupeg, Fylnetra, Neulasta, Nyvepria, Stimufend, or Ziextenzo, document intolerance or contraindication to the preferred pegfilgrastim products when the intolerance or contraindication is not expected with the requested product.

    • Preferred products: Fulphila and Udenyca.
    Note

    Unlisted Indications Require Medical Acceptance

    Requests for conditions not listed in the policy must meet the definition of a medically accepted indication.

    • The use must be approved under the Federal Food, Drug, and Cosmetic Act, or supported by one or more citations included in, or approved for inclusion in, one or more CMS-approved compendia.
    • The listed policy condition is Bone Marrow Transplantation (BMT).
    Denial Risk

    Insufficient Documentation May Prevent Approval

    Submit sufficient clinical documentation for the plan to verify that all medical-necessity requirements are met. Without the required supporting information, the request cannot be confirmed as meeting the policy requirements.

    • Include office chart notes, laboratory results, or other clinical information relevant to the request.
    Denial Risk

    Failure of Preferred-Product Trial Risks Denial

    For members in Blue Shield Select (PPO) and Blue Shield Medicare (PPO) plans, newly initiating Armlupeg, Fylnetra, Neulasta, Nyvepria, Stimufend, or Ziextenzo therapy must try both Fulphila and Udenyca first. Coverage is subject to step-therapy requirements unless the requested product is supported by an eligible intolerance or contraindication exception.

    • Failure to complete the required preferred-product trial creates a coverage denial risk.
    • Preferred products: Fulphila and Udenyca.
    • Exception documentation must show intolerance or contraindication not expected with the requested pegfilgrastim product.
    The biosimilar is compared with and associated with an existing FDA-approved biologic reference product.
    Route
    Subcutaneous administration
    TimingDay 1 following transplant
    Coverage frequencyOne dose
  1. Applies to newly initiated therapy with the specified products.